Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic Site License ACE Inhibitor Intolerance: A major driver of growth for the Aiirbs Datamonitor, April 2002   Description     Table of Contents        Enquire before Buying    Send to a Friend   This brief explores in detail the impact of generic ACE inhibitors on the Aiirb market, a theme raised in recent Datamonitor reports covering antihypertensive drugs. It is particularly topical, given the recent FDA approval of Sankyo Pharma/Forest Laboratories'' new angiotensin II receptor blocker, Benicar (olmesartan) for marketing in the US. The Brief draws together and builds on Treatment Algorithm survey findings in heart failure and hypertension for 7 countries, with epidemiology data, literature search material and a case study based on UK Department of Health prescription audit data for England. The Brief provides: * detailed analysis of the estimated proportion of hypertensive and heart failure patients that are ACE intolerant in the seven major pharmaceutical markets (US, Japan, Germany, France, Italy, Spain, UK) * clinical trial data investigating ACE inhibitor intolerance * a breakdown of the causes of ACE inhibitor intolerance * assessment of alternative therapies for ACE intolerant patients * summary of ACE inhibitor and Aiirb prescription trends in England from 1998 to 2001, and an analysis of the impact of generic enalapril within this market Customers who bought this item also bought Market Dynamics 2001: Anti-hypertensives - Aiirbs battle for supremacy Strastegic Perspectives 2001: Diabetic Hypertension - Towards Aggressive, Individual and Holistic Treatment Strategies Drugs of Tomorrow 2001: Hypertension - The Mounting Pressures Facing New Compounds Treatment Algorithms: Hypertension 3rd Edition - Opportunities In Resistant and Hypertensive Sub-Populations Drugs of Tomorrow 2001: Diabetes Treatment Algorithms 2002: Heart failure - managing chronic and acute patients Market Dynamics 2001: Hormonals Diabetic Nephropathy: Prevalence, Progression, Prevention and Potential Drugs of Tomorrow 2001: Antipsychotics - New Players in an Expanding Market Drugs of Tomorrow 2001: Anticoagulants - A pipeline flowing with future blockbusters Atherosclerosis: Strategic Audit of Marketplace Activity Issues and Implications COX-2 Inhibitors - Biology, Therapeutic Agents & Markets

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster